FilingSEC EDGAR424B5
Moleculin Biotech Increases ATM Offering Capacity to $19.7 Million
· SEC accepted
StageFiled
Filing content
The company filed a prospectus supplement to increase the maximum aggregate gross sales price of its common stock under the ATM agreement to $19.7 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…